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Split luciferasea b s t r a c t
Alzheimer’s disease (AD) is a neurodegenerative disease that causes progressive loss of cognitive
functions, leading to dementia. Two types of lesions are found in AD brains: neurofibrillary tangles
and senile plaques. The latter are composed mainly of the b-amyloid peptide (Ab) generated by amy-
loidogenic processing of the amyloid precursor protein (APP). Several studies have suggested that
dimerization of APP is closely linked to Ab production. Nevertheless, the mechanisms controlling
APP dimerization and their role in APP function are not known. Here we used a new luciferase com-
plementation assay to analyze APP dimerization and unravel the involvement of its three major
domains: the ectodomain, the transmembrane domain and the intracellular domain. Our results
indicate that within cells full-length APP dimerizes more than its a and b C-terminal fragments, con-
firming the pivotal role of the ectodomain in this process. Dimerization of the APP transmembrane
(TM) domain has been reported to regulate processing at the c-cleavage site. We show that both
non-familial and familial AD mutations in the TM GXXXG motifs strongly modulate Ab production,
but do not consistently change dimerization of the C-terminal fragments. Finally, we found for the
first time that removal of intracellular domain strongly increases APP dimerization. Increased APP
dimerization is linked to increased non-amyloidogenic processing.
 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction pathway). APP b-cleavage generates a membrane-anchored b C-The amyloid precursor protein (APP) is a ubiquitously expressed
type 1 transmembrane protein [1,2]. APP undergoes proteolysis via
two distinct pathways known as the amyloidogenic and the non-
amyloidogenic pathways. APP processing is initiated by the shed-
ding of the large ectodomain by either an a-secretase (non-
amyloidogenic pathway) or the b-secretase BACE1 (amyloidogenicterminal fragment (bCTF or C99), which is further cleaved by the
c-secretase complex to generate the Ab peptides. The 40 and 42
amino acids Ab isoforms (Ab40 and Ab42, respectively) are the
major constituents of the senile plaques, a typical lesion found in
the brain of patients with Alzheimer’s disease (AD) [4]. Mutations
responsible for inherited or familial AD cases (FAD) are located in
the APP or presenilin genes (PS1 and PS2). The presenilin proteins
are the catalytic subunits of the c-secretase. AD mutations
typically result in an increased Ab42/Ab40 ratio [2]. Imbalanced
production of Ab, along with its aggregation and accumulation in
the brain, may therefore play a critical role in the onset and
progression of AD [5].
Although Ab involvement in the pathology has been extensively
studied over the past decades, our knowledge of the physiological
function of APP and the cellular mechanism regulating its process-
ing remain remarkably incomplete. APP belongs with its two par-
alogs APLP1 and APLP2 to the APP-like protein family. Unique
features in each member of the family could account for its special-
ized and specific function [6]. Ten APP isoforms generated by
764 M. Decock et al. / FEBS Open Bio 5 (2015) 763–773alternative splicing of the APP transcript have been identified [3].
The major ones (APP695, APP751 and APP770) differ in their extra-
cellular domain by a Kunitz-type protease inhibitor (KPI) domain
present in non-neuronal isoforms (APP751 and APP770), but
absent in the neuronal one (APP695).
APP has been proposed to mediate dendritic spine arrangement,
neural cell migration and synapse formation, including neuromus-
cular junctions formation [7] that could underlie the neuromuscu-
lar phenotype observed in APP knock-out mice [8]. The possible
physiological role of APP can be related to its structural properties.
APP resembles a transmembrane receptor with an extracellular
region displaying features of a cell surface receptor or an adhesion
molecule [9,10]. These different functional regions include copper
binding and growth factor-like domains and are required for
homo- and heterophilic interactions [11,12]. For instance, APP
has been shown to interact with Notch [11,13], another major c-
secretase substrate, and even with the Ab peptide generated by
its processing [14]. APP dimerization is therefore likely to play a
pivotal role in its processing and function. Recent studies have
indicated that APP dimerization involves both the E1 and KPI
regions of the ectodomain [11,15–17] and GXXXG motifs of the
transmembrane (TM) domain [18,19]. GXXXG motifs are structural
determinants favoring close apposition of TM helices and forma-
tion of TM dimers [20,21,38]. The TM region of APP contains three
consecutive GXXXG motifs. The FAD A21G mutation (Ab number-
ing) known as the Flemish mutation [24] extends the GXXXG
interface by adding a fourth GXXXG motif and triggers Ab produc-
tion. This strongly suggests that TM interactions are involved in
pathophysiological processing of APP [19,23,25,26,33]. It is of
particular interest to clearly establish the relation between APP
dimerization and its processing, especially its cleavage at the c site.
Studies on APP dimerization have largely been carried out using bio-
chemical approaches (crosslinking, co-immunoprecipitation) [27]
focused on TM domain interactions in reconstituted micelles or
membrane bilayers [22] or have used purified peptides for structural
approaches [27–30]. Very few studies have addressed APP dimeriza-
tion in living cells. Although split fluorescent proteins assays
[13,31,32] have revealed a positive role of the KPI domain in APP
dimerization, the role of TM dimerization has appeared much more
controversial. It has even been suggested that the TM domain plays
only a marginal role in full-length APP dimerization [9,27].
Indeed, the extent of APP and CTFs dimerization in living cells is
poorly known. There is no information about the respective contri-
bution of its 3 major domains, and especially of its intracellular
domain in this process. The link between APP dimerization and
processing is controversial [27,36]. Here we use a new dynamic
and highly sensitive split protein assay, the split luciferase assay
[37] to define the role and the contribution of the different APP
regions to dimerization and clarify the correlation between its
dimerization and processing. Our major findings are that full-
length APP forms more dimers than APP b and aCTFs. Mutations
in the GXXXGmotifs, including FADmutants (Flemish), do not con-
sistently alter dimerization. Strikingly, deletion of intracellular
domain strongly favors dimerization. Finally, we found that the
extent of dimerization is not correlated to Ab production, but that
increased dimerization observed with APP lacking its intracellular
region is linked to increased non-amyloidogenic processing.2. Material and methods
2.1. Chemicals and reagents
Restriction enzymes, Taq DNA polymerase, all culture media,
penicillin-streptomycin solution and Lipofectamine transfection
reagent, Nu-Page Novex 4–12% Bis-Tris gels and buffers werefrom Life Technology Corporation (Carlsbad, CA). Fetal bovine
serum (FBS) for culture media was purchased from Thermo Scien-
tific (Rockford, IL). Transfection reagent Trans-IT2020 was from
Mirus Bio Corporation (Madison, WI). Analytical grade solvents,
salts and poly-L-lysine were from Sigma-Aldrich (St Louis, MO).
N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine-butyl
ester (DAPT) was from Calbiochem (Camarillo, CA). Protease inhibi-
tor cocktail was purchased from Roche (Basel, Switzerland). BCA
protein assay kit was from Pierce (Rockford, IL, USA). Nitrocellulose
membranes were obtained from GE Healthcare (Fairfield, CT). ECL
reagents were obtained from Perkin Elmer Inc. (Waltham, MA).
Gaussia luciferase substrate Coelenterazine native was purchased
from Prolume Ltd. (Pinetop, AZ). The luciferase cell lysis buffer
was from New England Biolabs (Ipswich, MA). The following pri-
mary antibodies were used: anti-amyloid b antibody, clone W0-2
(EMD Millipore, Billerica, MA), anti-amyloid precursor protein,
C-terminal antibody (Sigma-Aldrich, St Louis, MO), anti-GLuc anti-
body (New England Biolabs, Ipswich, MA). Fluorescent nucleic
acid stain DAPI was obtained from Sigma–Aldrich (St Louis, MO).
Secondary antibodies coupled to HRP were obtained from Amer-
sham Bioscience (Uppsala, Sweden) and fluorescent secondary
antibodies coupled to Alexa fluorochromes were from Life Technology
Corporation (Carlsbad, CA). Fluorescent mounting medium was from
DAKO (Agilent Technologies, Santa Clara, CA, USA).
2.2. Cells lines and cell culture
Chinese hamster ovary (CHO) cell lines were grown in Ham’s
F-12 medium. The medium was supplemented with 10% of
fetal bovine serum (FBS) and penicillin–streptomycin solution
(10 units-10 lg). All cell cultures were maintained at 37 C in a
humidified atmosphere (5% CO2).
2.3. Plasmids, site-directed mutagenesis and cloning
GCN4 leucine zipper split-luciferase constructs Zip-hGLuc1 and
Zip-hGLuc2 in pcDNA3.1 vectors were obtained from the group of
S.W. Michnick [37]. All the constructs expressing APP and APP frag-
ments fused to humanized Gaussia luciferase (hGluc) halves were
obtained by PCR amplification of APP sequences encoded by
expression vectors previously described [19] with forward and
reverse primers harboring the NotI and ClaI restriction sites,
respectively. PCR products were digested and further inserted in
the NotI/ClaI restrictions sites of the Zip-hGLuc1 and Zip-hGLuc2
constructs, removing the GCN4 leucine zipper sequence of the
backbone. All constructs were verified by full sequencing (Macro-
gen Europe, Amsterdam, The Netherlands). C83 mutants were
obtained by Quick-change site-specific mutagenesis (Stratagene,
La Jolla, CA) as previously described [31].
2.4. Cell transfection and treatment
CHO cells were transfected with Lipofectamin reagent 24 h after
seeding following manufacturer’s instructions. Plasmids express-
ing the split-luciferase proteins were cotransfected in a 1:1 ratio.
The control plasmid (Mock) was the corresponding empty vector.
MEF cells (PS+/+ and PS/) were transfected using Trans-
IT2020 according to the manufacturer’s instructions. CHO cells
were treated with DAPT for 15 h at a final concentration of 1 lM.
48 h after transfection, medium was collected, treated with pro-
tease inhibitors cocktail (Roche) and stored at 20 C for ECLIA
assay. Cells were harvested and lysed in Luciferase Cell Lysis Buffer
(New England Biolab) and pelleted by quick centrifugation at 4 C
for 1 min. Protein concentrations of cell lysates were measured by
the BCA protein assay kit (Pierce). Cell lysates were further used for
Gaussia luciferase assay and Western blotting.
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Samples were aliquoted in 5 ml polystyrene round-bottom
tubes at a final concentration of 10 lg of proteins in 20 ll in Luci-
ferase Cell Lysis Buffer. Native coelenterazine was reconstituted as
a stock solution of 1 mg/ml in methanol (stored frozen), diluted
30 min prior reading in DMEM without phenol red and used at a
final concentration of 20 lM. 50 ll of coelenterazine was added
to tubes and luminescence directly measured on a Sirius Lumi-
nometer (Berthold, Pforzheim, Germany).2.6. Western blotting
Ten lg of protein of cell lysates were heated for 10 min at 70 C
in loading buffer (Luciferase Cell Lysis Buffer with 0.5 M DTT and
staining Nupage blueTM), loaded and separated onto 4–12% Nupa-
geTM bis-Tris gel, and then transferred for 2 h at 30 V onto nitrocel-
lulose membranes. Ponceau Red staining was used to check gel
loading and transfer accuracy. After blocking with 5% non-fat milk
in PBS, membranes were incubated overnight at 4 C with one of
the primary antibodies: anti-amyloid b antibody, clone W0-2
(1/2500), anti-amyloid precursor protein, C-terminal antibody
(1/2000), anti-hGLuc antibody (1/2000). Membranes were washed
with PBS-Tween (0.005%) and incubated with the secondary anti-
bodies anti-mouse (1:10,000) or anti-rabbit (1:10,000) coupled to
peroxidase prior to ECL detection (GE Healthcare). Signals were
quantified with a Gel Doc 2000 imaging system coupled to a Quan-
tity OneTM software (Bio-Rad).
2.7. Immunocytochemistry
Cells were seeded on coverslips previously incubated with poly-
L-lysine (10 mg/ml). Prior to staining, cells were rinsed twice with
Opti-MEM (Life Technology Corporation) and fixed with 4%
paraformaldehyde (PFA) for 15 min. After 3 washes in PBS, cells
were permeabilized with PBS1X/0.3% Triton100X for 30 min and
blocked in PBS1X/fetal bovine serum 5%/0.1% Triton100X for
30 min. Primary antibodies were prepared in the blocking solution
and incubated O/N at 4 C. Primary antibodies used were anti-
human amyloid b antibody, clone W0-2 (1:2500), anti-amyloid
precursor protein, C-terminal antibody (1:2000), anti-hGLuc anti-
body (1:2000). After 3 washes in PBS, cells were incubated with
secondary antibodies (goat anti-mouse Alexa 465 and goat anti-
rabbit Alexa 488 and 465, 1:500 in blocking solution) and DAPI
(1:2000) for 1 h at 4 C. After 3 washes in PBS, cells were stored
in PBS-azide 0.1% at 4 C or mounted with fluorescent mounting
medium for coverslips. Pictures were acquired with an Evos
fluorescence microscope (Advanced Microscopy Group, Mill Creek,
Washington, USA) or with an Olympus Fluoview confocal
microscope (Olympus America Inc., Center Valley, Pennsylvania,
USA).2.8. Ab and sAPP measurements
Ab38, Ab40 and Ab42 peptides were quantified in the cell med-
ium as previously described [39] by the Ab multiplex electro-
chemiluminescence immunoassay (ECLIA) (Meso Scale Discovery,
Gaithersburg, MD). sAPPa and b were quantified using a sAPPa/
sAPPb multiplex ECLIA (Meso Scale Discovery). Cells were condi-
tioned in serum-free medium for 16 h before harvesting. Cell med-
ium was then collected and Ab or sAPP were quantified according
to the manufacturer’s instructions. Ab produced from split-
luciferase constructs was quantified with the human Ab specific
6E10 multiplex assay.2.9. Statistical analysis
The number of samples (n) in each experimental condition is
indicated in figure legends. The data were analyzed using
GraphPad Prism software by analysis of variance (ANOVA)
followed by unpaired t test (2 experimental conditions) or by
Bonferroni’s Multiple Comparison tests (more than 2 experimental
conditions).3. Results
3.1. APP and APP C-terminal fragments dimerization in cells analyzed
by luciferase complementation assays
To analyze human APP dimerization and the contribution of its
extracellular, juxtamembrane/transmembrane (JM/TM) and intra-
cellular (AICD) domains to this process, we generated vectors
expressing the full-length and truncated APP proteins (Fig. 1A)
fused to complementary humanized Gaussia luciferase (hGluc)
fragments referred to as hGluc1 and hGluc2 corresponding to
N-terminal and C-terminal moieties, respectively. C99 and C83 cor-
respond to b- and a-secretase cleavage products fused to the APP
signal peptide. APPDC corresponds to the APP protein truncated
after the KKKYQ sequence at the TM/intracellular interface. To
analyze the role of membrane GXXXG motifs in dimerization, we
generated 2 mutants modifying the interactive properties of the
GXXXG interface [19,24]. The first mutation corresponds to the
FAD Flemish mutation (A617G, APP695 numbering or A21G, Ab
numbering). It extends the GXXXG interface and helical structure
of the surrounding residues [29]. The double GG625/629LL mutant
(GG29/33LL, Ab numbering) hereafter referred as mutant 5 (mut5)
carries glycine to leucine mutations of the central GXXXG motif.
These mutations have been previously reported to affect interac-
tion of APP TM helices and strongly impair amyloidogenic process-
ing [19]. As a positive control, we used yeast transcription factor
GCN4 leucine zipper fusion proteins (Zip-hGLuc1 and Zip-
hGLuc2) [37]. The leucine zipper of GCN4 is a strong dimerization
domain. All the constructs generated for this study are represented
in Fig. 1A and B.
We first validated the luciferase complementation approach as
a tool to measure protein dimerization in living CHO cells by mea-
suring bioluminescence upon transfection with the GCN4 leucine
zipper hGLuc constructs. Western blotting of cell lysates indicated
that Zip-hGLuc1 and Zip-hGLuc2 were detected as 17 and 18 kDa
bands recognized by the polyclonal anti-hGLuc antibody
(Fig. 2A). Transfection of Zip-hGLuc1 and Zip-hGLuc2 alone did
not generate any bioluminescent signal whereas co-transfection
of both generated high levels of luciferase activity (Fig. 2A). Co-
expression of the hGLuc1 and hGLuc2 moieties alone (not fused
to any APP protein sequence) did not generate luciferase activity
(data not shown). This clearly validated the luciferase complemen-
tation approach as a very sensitive tool to measure dimerization in
cells.
We next compared dimerization of the APP, C99 and C83 con-
structs (Fig. 2B–D). Immunoblots performed with the W0-2 anti-
body, the hGLuc antibody or the APP C-terminal antibody (Cter)
showed that all constructs were expressed at readily detectable
levels. Immunolabelling of the double transfected cells indicated
a vesicular localization of the APP fusion proteins (Fig. 3),
particularly in the perinuclear region. APP hGLuc fusion proteins
had a subcellular distribution consistent with a post-ER/cis-Golgi
localization previously reported for endogenous APP and APP frag-
ments, but also for fusion constructs used in split protein assays
[27,31,40]. Signals of antibodies directed against human APP epi-
topes (W0-2) or hGLuc epitopes completely co-localized, excluding
Fig. 1. Schematic representation of the different APP split-luciferase constructs. (A) Schematic representation of the different human APP and APP C-terminal fragments
generated for fusion to the humanized Gaussia luciferase moieties (hGLuc). APPDC corresponds to APP695 deleted from its intracellular C-terminal domain (stop after the
KKKQY intracellular sequence). C99 and C83 correspond to the APP b and a C-terminal fragments, respectively. All the N-terminally truncated CTFs are fused to the APP signal
peptide (SP). Abbreviations are as follows: TM, transmembrane; JM, juxtamembrane; AICD, APP intracellular domain; ext, extracellular; int, intracellular. The positions of
Flemish and mutant 5 (mut5) mutations are underlined and amino acid substitutions are in red. The cleavage sites of a (a)-, b (b)- and c (c and e)-secretases are indicated by
arrows. (B) Schematic representation of APP constructs fused to hGLuc moieties (hGLuc1 and hGLuc2). The epitopes of the human-specific W0-2 antibody, the APP C-terminal
and hGLuc antibodies are indicated.
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could be responsible for bioluminescent signals.
After normalization to expression levels of the fusion proteins
(Fig. 4A), our results indicated that APP dimerizes significantly
more (5 times) than its a and b C-terminal fragments (Fig. 4B).
Similar results were obtained with all the antibodies used for cell
lysate quantifications (W0-2, Cter or hGLuc). These observations
suggest that C-terminal fragments of APP (b or aCTFs) form dimers
to a smaller extent than full-length APP. We further investigated
this hypothesis by treating transfected cells with DAPT, a
c-secretase allosteric inhibitor, inducing the accumulation of
c-secretase substrates in cells. DAPT effects were consistent with
those observed on non-tagged human APP in the same cells
(Fig. 5A) [19]. DAPT treatment resulted mainly in the accumulation
of aCTFs (Fig. 5A and B). Bioluminescence measured after DAPT
treatment indicated a small -although significant- decrease in
APP dimerization, but importantly no increase in aCTF or bCTF
dimerization was measured under the same conditions (Fig. 5C).
Similar results were observed in PSdKO mouse embryonic fibrob-
last (MEFs) that are devoid of c-secretase activity (data not
shown). Together, these data indicate that APP CTFs dimerize muchless than full-length APP. Their accumulation by a c-secretase inhi-
bitor did not increase dimerization, suggesting that only a pool of
CTFs are forming dimers, which are not accessible to cleavage by
c-secretase. DAPT treatment efficiently inhibited the c-cleavage
of APP split luciferase constructs, as evidenced by the strong inhi-
bition of Ab release (Fig. 5D).
3.2. GXXXG motifs are not critical for CTFs dimerization
Our recent work showed that mutation of the GXXXG motifs
modifies TM interactions of the APP CTFs [19]. To determine
whether GXXXG motifs are involved in CTFs homo-dimerization
by a quantitative approach, we compared dimerization of C99 (cor-
responding to the bCTF of APP), C99 with the Flemish mutation or
C99 mut5 (Fig. 1A). Both C99 mutants exhibited the same dimer-
ization profile as wild-type C99 (Fig. 6A). Similar experiments were
carried out with C83 constructs, corresponding to the APP aCTF.
C99 and C83 constructs had similar expression profiles (Fig. 6B).
Both the Flemish mutant and mut5 showed a slight but significant
decrease in dimerization of C99. For C83, dimerization of the
Flemish mutant was slightly but significantly increased, whereas
Fig. 2. Dimerization of APP and APP C-terminal fragments in living cells measured by the split-luciferase complementation assay. (A) Validation of the luciferase
complementation assay for measuring protein dimerization in CHO cells. Cells were transfected with the control empty vector (mock) or the GCN4 leucine zipper–coding
sequences fused to hGLuc moieties (Zip-hGluc1 and 2). Expression of the fusion proteins was checked in cell lysates by Western blotting with the hGLuc antibody (top).
Luciferase activity (bioluminescence) was measured and expressed as RLU (bottom). Values (means ± SEM) are representative of 3 independent experiments (n = 4 in each
experiment). ***p < 0.0001, as compared to control (mock). APP-hGLuc1 and 2 (B), C99-hGLuc1 and 2 (C) or C83-hGLuc1 and 2 proteins (D) were transfected in CHO cells.
Protein expression was monitored in cell lysates by Western blotting with the W0-2 and hGluc antibodies (top panels). Luciferase activity was measured and expressed as
RLU (bottom). Values (means ± SEM) are representative of 3 independent experiments (n = 4 in each experiment). ***p < 0.0001, as compared to control (mock).
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motifs was reported to dramatically impact Ab production
(Fig. 6C). We previously showed [19,29] that the Flemish FAD
mutation increased Ab production whereas mutant 5 strongly
decreased it. Our data (Fig. 6) indicate that mutations of GXXXG
motifs strongly affect APP c-cleavage without a corresponding
change in dimerization of the APP CTFs.
3.3. APP C-terminal region regulates APP dimerization and non-
amyloidogenic processing
We finally examined the role of the APP intracellular C-terminal
domain in dimerization. We generated APPDC split-luciferase con-
structs, corresponding to APP deleted from its intracellular region
(Fig. 1). Indeed, much attention has been given so far to the contri-
bution of the extracellular and TM domains to APP dimerization,
but nothing is known about the role of its intracellular region. Both
APP and APPDC were recognized by the W0-2 and hGLuc antibod-
ies, and both constructs were expressed at similar levels (Fig. 7A).
Immunostaining (Fig. 7C) indicated that APP and APPDC displayed
similar subcellular distribution profiles. Results in Fig. 7A clearlyshowed that APPDC formed more dimers than APP in cells. Expres-
sion of C99 constructs identically lacking their intracellular
domains (C55) led to the same increased dimerization (data not
shown). To know whether this drastic change in dimerization is
related to APP metabolism, we measured sAPPa and sAPPb levels
produced by those cells. Soluble APPa and sAPPb production are
indicators of the ectodomain shedding occurring as a first step of
the non-amyloidogenic and amyloidogenic processing, respec-
tively. Cells expressing APPDC-hGLuc showed increased sAPPa
levels and reduced sAPPb production. The ratio between sAPPa
and sAPPb significantly increased, indicating that APPDC metabo-
lism is shifted towards non-amyloidogenic processing.4. Discussion
Dimerization appears to be a key modulator of APP processing
and function. APP shares many features with cell adhesion mole-
cules and TM receptors [9]. APP homo- and hetero-association
are involved in trans–cellular interactions [11]. Homodimerization
was proposed to be directly correlated to amyloidogenic processing
Fig. 3. Localization of split-luciferase constructs in CHO cells. Cells were co-transfected with the two split-luciferase constructs expressing either APP C99 or C83. Nuclei were
stained with DAPI, and APP fusion constructs were stained by the W0-2 and/or hGLuc antibodies. Scale bar: 5 lm.
Fig. 4. Comparison of APP and APP C-terminal fragment dimerization. Cells were transfected with the control empty vector (mock), the APP-hGLuc1 and 2, C99-hGLuc1 and 2
or C83-hGLuc1 and 2 constructs. (A) Protein expression was monitored in cell lysates byWestern blotting with the W0-2, Cter or hGLuc antibodies. (B) Luciferase activity was
measured and expressed as RLU normalized to APP (set to 100%). Values (means ± SEM) are representative of 3 independent experiments (n = 4 in each experiment).
***p < 0.001, n.s. (non-significant), as compared to APP-hGLuc1 and 2.
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interaction motifs leads to impaired Ab production [18,19],
suggesting that the formation of dimeric amyloidogenic CTFs is a
control mechanism of APP c-cleavage. However, whether dimer-
ization promotes or inhibits dimerization itself has been a matter
of debate [25,26]. Recent studies indicated that, in contrast to Ab
production, dimerization is not altered in FAD mutants [27],challenging the hypothesis that dimerization is involved in amy-
loidogenic processing. Indeed, the extent of APP and APP CTFs
dimerization in cells, its relation to amyloidogenic processing
and the contribution of the different APP domains in this process
remain unclear and poorly known.
APP homo- and/or hetero-dimerization have been reported so
far using different approaches, including co-immunopreciptation
Fig. 5. Effects of gamma-secretase inhibition on APP C99 and C83 dimerization. CHO cells transfected with the empty vector (mock) or the luciferase constructs expressing
either APP, C99 and C83 or APP-hGLuc1 and 2, C99-hGLuc1 and 2 and C83-hGLuc1 and 2. Cells were treated with DAPT 1 lM for 18 h. (A) Expression of the non-tagged
proteins and effect of the treatment on metabolism were checked in cell lysates by western blotting with APP specific antibodies (W0-2 and Cter). (B) Expression of the hGLuc
fusion proteins was checked in cell lysates by Western blotting with the hGLuc antibody and APP specific antibodies (W0-2 and Cter). (C) Luciferase activity measured was
expressed as RLU normalized to APP-hGLuc1 and 2 (set to 100%). Values (means ± SEM) are representative of 3 independent experiments (n = 4 in each experiment). *p < 0.05,
***p < 0.001, n.s. (non-significant), as compared to APP-hGLuc1 and 2. (D) Gamma-secretase inhibition was confirmed by monitoring Ab38, Ab40 and Ab42 production by
ECLIA in the culture medium of cells expressing APP-hGLuc1 and 2 or C99-hGLuc1 and 2. Results are given as Ab levels in pg/ml. Values (means ± SEM) are representative of 3
independent experiments (n = 4 in each experiment). *p < 0.05 and ***p < 0.001, as compared to non-treated cells.
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protein assays [19,27,41]. We recently used the bimolecular fluo-
rescence complementation (BiFC) method, or split-YFP, to analyze
dimerization of APP695 and APP751 isoforms [17,31]. This method
has gained popularity in the field to study protein–protein interac-
tions in living cells [13,42]. Its major advantage is to allow direct
visualization of protein interactions without the use of biochemical
reagents or antibodies that might themselves modify the dimeriza-
tion properties of the proteins investigated. The major drawbacks
of BiFC are that the fluorescent protein halves are prone to self-
assembly independent of a protein–protein interaction event, and
that the split position promotes irreversible self-interaction ofthe two non-fluorescent fragments, which may result in the
detection of false positive signals [43]. Here we used the split
Gaussia luciferase assay, a more recent, quantitative and dynamic
complementation method to circumvent drawbacks of previous
split protein approaches [37]. The humanized Gaussia princeps
luciferase (hGLuc) can generate over 100-fold higher biolumines-
cent signal than other luciferases and is the smallest known
coelenterazine-using luciferase, making it an ideal candidate for
protein complementation assays.
APP and the various APP C-terminal fragments fused to the
split-protein used in our study were readily expressed in CHO cells
and detectable by Western blotting by different antibodies, thus
Fig. 6. Involvement of GXXXG motifs in CTF dimerization and Ab production. CHO cells were transfected with C99-hGLuc1 and 2 or C83-hGLuc1 and 2 and their GXXXG
Flemish (Fle) and mutant 5 (mut5) corresponding mutants. (A) Cells transfected with the control empty vector (mock), the C99-hGLuc1 and 2, C99Fle-hGLuc1 and 2 or
C99mut5-hGLuc1 and 2 proteins. Protein expression was monitored in cell lysates byWestern blotting with theW0-2 or hGluc antibodies (top panels). Luciferase activity was
measured and expressed as RLU normalized to non-mutated C99 (bottom). Values (means ± SEM) are representative of 5 independent experiments (n = 4 in each experiment).
*p < 0.05, **p < 0.01 and ***p < 0.001, as compared to C99-hGLuc1 and 2. (B) Cells transfected with the control empty vector (mock), the C83-hGLuc1 and 2, C83Fle-hGLuc1 and
2 or C83mut5-hGLuc1 and 2 proteins. Protein expression was monitored in cell lysates by Western blotting with the Cter or hGLuc antibodies (top panels). Luciferase activity
was measured and expressed as RLU normalized to non-mutated C83 (bottom). Values (means ± SEM) are representative of 3 independent experiments (n = 4 in each
experiment). *p < 0.05, **p < 0.01 and n.s. (non significant), as compared to C83-hGLuc1 and 2. (C) Ab 38, 40 and 42 production for C99-hGLuc1 and 2, C99Fle-hGLuc1 and 2 or
C99mut5-hGLuc1 and 2 was measured by ECLIA in the culture media and given in pg/ml. Values (means ± SEM) are representative of 3 independent experiment (n = 4 in each
experiment). ***p < 0.001, as compared to non-mutated C99.
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cent protein content. This is an important asset when compared to
the split YFP approach [31], in which quantitative comparison of
protein dimerization is more difficult to achieve. We also checked
that the co-expression of the hGLuc halves alone do not generate a
bioluminescent signal (data not shown), excluding the possibility
that the luciferase protein halves self-assemble independently of
a protein–protein interaction event, a critical possible bias in split
protein assays [43]. Grafting hGLuc halves at the C-terminus does
not impair APP subcellular localization or processing. The split
luciferase assays we developed appeared therefore as a very sensi-
tive and reliable tool to decipher the mechanisms of APP dimeriza-
tion in cells.
We first observed that full length APP dimerizes more than its
C-terminal fragments. At similar expression levels, the extent ofAPP dimerization is at least 5 times higher than for C99 or C83.
C99 and C83 seem to have only poor and restricted dimerization
properties [30]. Their accumulation upon cell treatment with a
c-secretase inhibitor (DAPT) does not increase the bioluminescent
signal. This observation strongly argues that CTF dimers are not
substrates of the c-secretase. Under the same conditions (DAPT
treatment), APP dimerization was slightly but significantly
reduced although cellular levels of the APP protein were
unchanged. One possible interpretation to this unexpected obser-
vation is that the accumulation of CTFs (endogenous or hGLuc
tagged) upon DAPT treatment could interfere with full-length
APP dimerization. This seems to be indeed the case since
co-transfection of APP-hGLuc and C83-hGLuc formed dimers to
a lesser extent than APP homodimers (see Supplementary
Fig. S1).
Fig. 7. Influence of the intracellular in APP dimerization. (A) Protein expression was monitored in cell lysates by Western blotting with the W0-2 or hGluc antibodies (left
panel). Luciferase activity was measured and expressed as RLU normalized to APP (set to 100%, right panel). Values (means ± SEM) are representative of 2 independent
experiment (n = 4 in each experiment). ***p < 0.001, as compared to APP-hGLuc1 and 2. (B) sAPPa and b production of APP-hGLuc1 and 2 and APPDC-hGLuc1 and 2 constructs
were monitored by ECLIA in the culture media of cells and are given in ng/ml. *p < 0.05 and ***p < 0.001, as compared to non-transfected cells or as indicated. Ratio of sAPPa on
sAPPb produced was calculated in the same experiments. **p < 0.01, as compared to APP-hGLuc1 and 2 (C) Immunostaining of cells co-expressing APP or APPDC constructs of
either. Nuclei were stained with DAPI, and APP fusion constructs were stained by the W0-2 and/or hGLuc antibodies. Scale bar: 5 lm.
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observed in cells and that dimers are formed in the early secretory
pathway [31]. Our results are in line with these observations, and
confirm that determinants playing a major role in APP dimeriza-
tion (E1 and KPI domains) are located in its extracellular region
[15,31]. Dimerization driven by ectodomain regions appears as a
key mechanism for APP trafficking to the cell surface [15,16]. Much
more attention has been recently given to dimerization of the APP
JM/TM regions and the role of these regions in amyloidogenic pro-
cessing and Ab production. APP contains 3 in-register GXXXG
motifs that start in the extracellular JM sequence and continue into
the TM domain. These motifs are well known to stabilize TM
protein interactions by close apposition of TM a-helices [44,45].Structural approaches have established that APP JM/TM sequences
interact through GXXXG motifs interfaces [28–30]. Mutations of
these motifs strongly modulate their interaction and impair Ab
production [18,19]. We found in a previous study [17] that muta-
tion of GXXXG motifs did not affect dimerization of full length
APP. We confirmed by the split luciferase system that mutation
in a critical GXXXG motif (mut5) has no effect on full-length APP
dimerization (see Supplementary Fig. S2). In addition, GXXXG
mutations did no modify the sAPPa/sAPPb ratio, excluding the
hypothesis that they indirectly contribute to the production of
Ab by facilitating the shedding of the of APP ectodomain through
the a- or b-secretase pathways. This strongly suggested that
GXXXG motifs might play a critical role in APP CTF dimerization,
772 M. Decock et al. / FEBS Open Bio 5 (2015) 763–773after the removal of the bulky ectodomain by a- or b-secretase. We
directly addressed this point by mutating the GXXXG motifs in C99
and C83 (corresponding to b and aCTF, respectively) and measur-
ing the effect on dimerization by the split luciferase assay. We ana-
lyzed 2 different mutants: mut5 with mutations of the central
GXXXG motif (GG29/33LL) disrupting the GXXXG interface and
the FAD Flemish mutant (A21G) adding a fourth in register GXXXG
motif extending the GXXXG interface. These mutations had only a
very moderate effect on C83 and C99 dimerization. No consistent
effect was measured of C83 mut5 and A21G constructs. Decreased
dimerization was measured for both mutated C99 constructs,
although the effect was moderate. These observations first indicate
that C99 and C83 dimerization might be different, due to determi-
nants located between the a- and b-cleavage sites. Contrary to
what was previously suggested, mutation of GXXXG motifs do
not trigger the formation of stable TM dimers through the GXXXA
motif located downstream [19]. Importantly, there was no direct
relationship between the effects of the mutation on dimerization
and Ab production. The Flemish mutation significantly increased
Ab release, whereas mut5 blocked it. This is consistent with very
recent results showing an independent relationship between APP
dimerization and c-secretase processivity [26,27,36]. Rather than
changing dimerization, mutation of glycine residues in the GXXXG
motifs might induce a conformational change increasing the fitness
of the substrate for c-secretase activity, and thus Ab production
[29]. In fact, the GXXXG motif has been shown to interact with
NSAIDs and cholesterol, playing the role of a cholesterol sensor
pocket [30,35]. JM/TM regions are sensitive to the membrane lipid
context and are targeted by drugs acting as c-secretase modula-
tors, but probably independent of their dimerization properties.
It would be of interest to evaluate with the split luciferase assay
how these compounds impact dimerization, if GXXXG mutants
show different sensitivities, and how they can be related to their
modulatory effect on Ab production.
One major finding in this study is that deletion of APP intracel-
lular domain importantly increased its dimerization. So far, the
intracellular domain has never been shown to influence APP
dimerization. We built AICD split luciferase constructs and found
that AICD does not dimerize by itself (data not shown). One possi-
ble explanation could be that the interaction of the APP intracellu-
lar region with proteins like G0 protein or Fe65 [46,47] favors
dimerization. Indeed, APP has been shown to interact with adaptor
proteins like Fe65 by its YENPTY intracellular motif [48,49] and
this association could impair or compete with dimerization. When
we expressed Fe65 together with APP in CHO cells we did not mod-
ify APP dimerization measured by split-luciferase (see Supplemen-
tary Fig. S3). This does not exclude the possibility that other
unknown interacting protein modulate dimerization. An alterna-
tive hypothesis could be that dimerization is related to trafficking,
which in turn impacts processing. APPDC is directed to the secre-
tory pathway but cannot be internalized properly due to loss of
the NPTY internalization motif [31,50]. At this stage, we cannot
define whether increased dimerization of APPDC is the cause or a
consequence of the reduced endocytosis, but we can propose that
the amount of APPDC stays high in cells because they fail to be
endocytosed in compartments where they are further processed.
This would in turn favor its non-amyloidogenic processing, known
to occur close to the cell surface. This is consistent with our obser-
vations, indicating that increased dimerization of APPDC is linked
to increased cleavage by a-secretase, inducing a shift towards
non-amyloidogenic pathway. Interestingly, compounds that have
been shown to destabilize dimerization of the APP ectodomain
indeed regulate cleavage by a-secretase [34]. However, the
question of whether a- secretase cleaves APP dimers, or whether
dimerization favors trafficking to compartments where
a-cleavage occurs, remains totally open.5. Conclusion
We used the recent split luciferase assay to study APP dimeriza-
tion in cells. In contrast to what was suggested in previous studies,
we found that the APP CTFs (C99 and C83) dimerized at a low level
when compared to full-length APP. Mutation of the TM interaction
GXXXG motifs did not significantly affect CTF dimerization. Com-
bining dimerization studies and measurement of Ab production,
we found that there is no direct relationship between APP dimer-
ization and c-cleavage. In fact, major determinants controlling
APP dimerization appear to be its intracellular domain. Increasing
APP dimerization favors its non-amyloidogenic processing. This
brings new and important insights on the different regions driving
APP dimerization, and the relationship between dimerization and
processing.
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